Duran, Gulay GulbolKucuk, Meral UrhanAlgul, OztekinTerzi, Menderes Yusuf2024-09-182024-09-1820201516-89131678-4324https://doi.org/10.1590/1678-4324-2020190364https://hdl.handle.net/20.500.12483/7265Chronic inflammation is a common indication of several diseases, e.g. asthma, chronic obstructive pulmonary disease (COPD), atherosclerosis, etc. Benzimidazole derivatives are preferable compounds to design new analgesic and anti-inflammatory substances due to their unique biological features. We aimed to investigate the effect of a newly synthesized benzimidazole derivative, ORT-83, on A549 human lung adenocarcinoma cell line. ORT-83 was synthesized, and a non-cytotoxic concentration of ORT-83 on A549 cells was detected with MTT assay. To analyze the anti-inflammatory effect of ORT-83, an inflammatory cell culture model was established by stimulating A549 cell line with IL1-beta (10 ng/ml). After 2 hours of treatment with IL1-beta to induce inflammation, A549 cells were exposed to ORT-83 (0.78 mu g/ml) for 24 hours. Thereafter gene expression analyses were performed with qRT-PCR. We found that ORT-83 significantly suppressed the gene expression levels of the proinflammatory cytokines; IL-6, NFkB, and TNF-alpha. However, the increased levels of IL-10 (2.8 folds) by IL-1 beta induction did not change after ORT-83 and/or dexamethasone (Dex: positive control) treatments. While Dex; a COX-2 inhibitor, reduced the COX-2 expression level in inflammatory cells from 10.03 folds to 0.71 folds, ORT-83 reduced its level to 4.37 folds. iNOS expression levels did not change in any experimental groups. In conclusion, we showed that ORT-83 exerted its anti-inflammatory effects by repressing the gene expression of proinflammatory cytokines in the inflammation-induced A549 cell line. Although ORT-83 had a weaker COX-2 inhibitory effect compared to Dex, it was shown to be still a strong anti-inflammatory compound.eninfo:eu-repo/semantics/openAccessA549benzimidazoleinflammationanti-inflammatoryArticle6310.1590/1678-4324-20201903642-s2.0-85090269549Q2WOS:000568669100001Q4